CONTACT US
CONTACT US

why Libria?

The detection of early signs of cognitive decline is crucial but awareness and actions are taken only at a late stage of the decline process.
Usually, the screening process is performed once or sparsely over time whilst diagnosis, treatment, and care plans would benefit from long-term monitoring.
Our main focus is addressing age-related cognitive decline providing digital tools that include effective assessment of cognitive decline and brain training in a way that can be available every day, in the comfort of people’s homes or workplaces, boosting effectivity, reliability and compliance.

Dementia affects 47 million people worldwide

(approx. 5% of the world’s elderly population) and predicted to increase to 75 million in 2030. 1 new case every 3 seconds

Dementia costs were estimated at $818 billion,

equivalent to 1.1% of GGDP*. By 2030, it is estimated to rise up to $ 2 trillion.

*Global Gross Domestic Product.

Dementia is underdiagnosed

If a diagnosis is made, it is typically at a late stage in the disease progression.

At Aequilibria Health we are developing a revolutionary digital platform to address a wide range of cognitive issues that can arise during ageing.

We called this tool

Are you interested in Libria?
Contact us!

Facebook Linkedin
Privacy Policy

All Rights Reserved | Aequilibria™ Health Ltd 2024